G protein βγ subunits regulate cardiomyocyte hypertrophy through a perinuclear Golgi phosphatidylinositol 4-phosphate hydrolysis pathway. by Malik, S et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Biochemistry and Molecular Biology
Faculty Papers Department of Biochemistry and Molecular Biology
3-15-2015
G protein βγ subunits regulate cardiomyocyte
hypertrophy through a perinuclear Golgi
phosphatidylinositol 4-phosphate hydrolysis
pathway.
S Malik
Department of Pharmacology and Physiology, University of Rochester
R G deRubio
Department of Pharmacology and Physiology, University of Rochester
M Trembley
Department of Pharmacology and Physiology, University of Rochester
R Irannejad
Department of Psychiatry, University of California, San Francisco
Philip B Wedegaertner
Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philip.Wedegaertner@jefferson.edu
See next page for additional authorsLet us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/bmpfp
Part of the Medical Molecular Biology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Biochemistry and Molecular Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Malik, S; deRubio, R G; Trembley, M; Irannejad, R; Wedegaertner, Philip B; and Smrcka, A V, "G
protein βγ subunits regulate cardiomyocyte hypertrophy through a perinuclear Golgi
phosphatidylinositol 4-phosphate hydrolysis pathway." (2015). Department of Biochemistry and
Molecular Biology Faculty Papers. Paper 85.
http://jdc.jefferson.edu/bmpfp/85
Authors
S Malik, R G deRubio, M Trembley, R Irannejad, Philip B Wedegaertner, and A V Smrcka
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/bmpfp/85
1188 | S. Malik et al. Molecular Biology of the Cell
MBoC | ARTICLE
G protein βγ subunits regulate cardiomyocyte 
hypertrophy through a perinuclear Golgi 
phosphatidylinositol 4-phosphate hydrolysis 
pathway
S. Malika, R. G. deRubioa, M. Trembleya, R. Irannejadb, P. B. Wedegaertnerc, and A. V. Smrckaa
aDepartment of Pharmacology and Physiology, University of Rochester, Rochester, NY 14642; bDepartment of 
Psychiatry, University of California, San Francisco, San Francisco, CA 94158; cDepartment of Biochemistry and 
Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107
ABSTRACT We recently identified a novel GPCR-dependent pathway for regulation of car-
diac hypertrophy that depends on Golgi phosphatidylinositol 4-phosphate (PI4P) hydrolysis 
by a specific isoform of phospholipase C (PLC), PLCε, at the nuclear envelope. How stimuli are 
transmitted from cell surface GPCRs to activation of perinuclear PLCε is not clear. Here we 
tested the role of G protein βγ subunits. Gβγ inhibition blocked ET-1–stimulated Golgi PI4P 
depletion in neonatal and adult ventricular myocytes. Blocking Gβγ at the Golgi inhibited ET-
1–dependent PI4P depletion and nuclear PKD activation. Translocation of Gβγ to the Golgi 
stimulated perinuclear Golgi PI4P depletion and nuclear PKD activation. Finally, blocking Gβγ 
at the Golgi or PM blocked ET-1–dependent cardiomyocyte hypertrophy. These data indicate 
that Gβγ regulation of the perinuclear Golgi PI4P pathway and a separate pathway at the PM 
is required for ET-1–stimulated hypertrophy, and the efficacy of Gβγ inhibition in preventing 
heart failure maybe due in part to its blocking both these pathways.
INTRODUCTION
G protein–coupled receptors (GPCRs) regulate many aspects of car-
diac function, including cardiac contractility and hypertrophic 
growth. One of the key GPCR-regulated pathways in cardiomyo-
cytes is the phosphoinositide-specific phospholipase C (PI-PLC) 
signaling pathway, which hydrolyzes plasma membrane (PM) phos-
phatidylinositol 4,5-bisphosphate (PIP2) to produce inositol tris-
phosphate (IP3) and diacylglycerol (DAG). IP3-dependent calcium 
release in the nucleus and DAG-dependent activation of protein ki-
nase D (PKD) are two of the critical signals involved in regulation of 
cardiac hypertrophic growth (Vega et al., 2004; Wu et al., 2006). Gq 
has been shown to drive cardiac hypertrophy (Knowlton et al., 1993; 
D’Angelo et al., 1997) and is known to activate PLCβ (Smrcka et al., 
1991; Taylor et al., 1991). Indeed, PLCβ1 has been directly impli-
cated in α1-adrenergic receptor–dependent hypertrophic growth of 
neonatal rat ventricular myocytes (NRVMs; Filtz et al., 2009).
Our laboratory has identified unique roles for a distinct isoform 
of PI-PLC, PLCε, in regulation of various aspects of cardiac function 
(Smrcka et al., 2012). PLCε provides a link between β-adrenergic 
receptor activation and type 2 ryanodine receptor (Ryr2)–dependent 
calcium release in the regulation of cardiac contractility (Wang et al., 
2005; Oestreich et al., 2007; Oestreich et al., 2009). PLCε is also re-
quired for development of the pressure overload model of cardiac 
hypertrophy in mice and is downstream of multiple receptor-depen-
dent stimuli in isolated ventricular myocytes (Zhang et al., 2011, 
2013). Like all PI-PLCs, PLCε hydrolyzes PIP2, but it has distinct regu-
latory features, in that it is directly activated by small GTPases, in-
cluding Ras, Rap, and Rho (Smrcka et al., 2012). PLCε can also be 
activated by G protein βγ subunits, although direct interactions have 
not been demonstrated (Wing et al., 2001). These regulatory 
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envelope (Figure 1B). Treatment with brefeldin A disrupts the lo-
calization of the perinuclear PI4P probe (Figure 1B) and the Golgi-
specific 58K protein (Figure 1C) but does not affect the distribution 
of mAKAP, supporting the idea that PI4P and mAKAP are in dis-
tinct but closely associated compartments—Golgi and nuclear 
envelope—that are not readily distinguished by conventional light 
microscopy.
To determine whether Gβγ is involved in perinuclear Golgi PI4P 
hydrolysis, we monitored perinuclear fluorescence intensity associ-
ated with GFP-FAPP-PH in NRVMs in the presence and absence of 
features potentially place it downstream of any signals that can acti-
vate these G proteins.
We recently identified a novel mechanism for PLCε-dependent 
regulation of cardiac hypertrophy (Zhang et al., 2013). PLCε scaf-
folded at the nuclear envelope in cardiac myocytes by direct bind-
ing to muscle-specific A kinase anchoring protein (mAKAP) hydro-
lyzes perinuclear Golgi phosphatidylinositol 4-phosphate (PI4P) to 
generate local DAG and regulate nuclear PKD. PKD is a key kinase 
that phosphorylates histone deacetylase (HDAC) to stimulate hyper-
trophic gene expression, and deletion of PKD inhibits development 
of pressure overload and angiotensin II–induced cardiac hypertro-
phy (Vega et al., 2004; Fielitz et al., 2008). In cardiac myocytes, the 
Golgi apparatus intimately surrounds the nuclear envelope, and lo-
cal signals generated at the Golgi in close proximity to the nucleus 
can regulate nuclear PKD activation. We recently proposed that 
Golgi-localized perinuclear DAG generated by mAKAP-scaffolded 
PLCε is necessary to maintain activation of PKD at the nucleus, since 
DAG is not diffusible from membranes (Zhang et al., 2013). In these 
studies, treatment of cardiac myocytes with endothelin-1 (ET-1) 
stimulated the PLCε pathway to regulate nuclear PKD. The question 
that arises is how the signal is transmitted from PM ET-1A receptors 
to PLCε at the perinuclear Golgi apparatus. ET-1AR can couple to 
multiple different G proteins, including G12/13 and Gq, which in 
turn lead to activation of intracellular signaling proteins such as Ras 
or Rho that could directly activate PLCε.
A pathway involving PKD activation at the Golgi has been shown 
to be involved in vesicular transport and secretion in cultured cell 
lines and involves G protein βγ subunits (Jamora et al., 1999; Diaz 
Anel and Malhotra, 2005; Campelo and Malhotra, 2012). Some of 
these studies suggest that Gβγ directly binds and activates PKD, but 
there is evidence that Gβγ-dependent regulation of PLC activity is 
required to produce DAG at the Golgi for PKC and PKD activation 
(Diaz Anel, 2007; Irannejad and Wedegaertner, 2010). The substrate 
for PLC in this reaction was presumed to be PIP2 but was not de-
fined. Exactly how Gβγ is regulated at the Golgi is unclear, but it has 
been shown that Gβγ can translocate from the PM to the Golgi to 
regulate Golgi fission (Chisari et al., 2007; Saini et al., 2007, 2010).
The similarities between the Golgi trafficking and cardiac hyper-
trophy pathways and the fact that PLCε can be regulated by Gβγ 
suggests the idea that Gβγ mediates the signaling downstream of 
ET-1 to regulate PLCε-dependent PI4P hydrolysis, PKD activation, 
and cardiomyocyte hypertrophy. Blocking Gβγ signaling with either 
protein- or small molecule–based inhibitors has profound salutary 
effects on heart failure in vivo and in cardiomyocytes in culture (Koch 
et al., 1995; Rockman et al., 1998; Casey et al., 2010; Rengo et al., 
2011). Here we provide evidence that Gβγ is required for ET-1–de-
pendent perinuclear PI4P hydrolysis, nuclear PKD activation, and 
NRVM hypertrophy. This indicates that one of the potential mecha-
nisms by which Gβγ blockade inhibits development of heart failure 
is through inhibition of this novel pathway.
RESULTS
ET-1–dependent perinuclear PI4P hydrolysis relies on 
Gβγ signaling
As we previously reported, in NRVMs transfected with the PI4P-
specific probe green fluorescent protein–four-phosphate adapter 
protein–pleckstrin homology domain (GFP-FAPP-PH), a perinu-
clear fluorescent ring is observed by confocal fluorescence micros-
copy that strongly colocalizes with the Golgi apparatus and is 
identified with an antibody recognizing a Golgi-specific 58K pro-
tein (Figure 1A; Zhang et al., 2013). The localization of PI4P 
also appears to overlap with mAKAP associated with the nuclear 
FIGURE 1: PI4P-associated GFP-FAPP-PH fluorescence colocalizes 
with a Golgi marker and is closely associated with nuclear envelope–
localized mAKAP. (A) NRVMs were transduced with adenovirus 
expressing GFP-FAPP-PH. Cells were fixed and stained for Golgi-
specific 58K protein (Alexa Fluor 546 secondary antibody) and imaged 
for GFP and red fluorescence. (B) Same as A, except that cells were 
stained for mAKAP instead of Golgi and treated with and without 
10 μM brefeldin A for 20 min as indicated. (C) Cells were treated for 
the indicated times with brefeldin A, fixed, and costained for mAKAP 
and Golgi-specific 58K protein. Scale bars, 10 μm.
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of GRK2 (GRK2ct), a well-established Gβγ 
blocker. In cells transfected with GRK2ct, 
ET-1–dependent PI4P depletion was com-
pletely abolished (Figure 2C). Taken 
together, these data indicate that Gβγ sig-
naling is required for ET-1–dependent stim-
ulation of perinuclear PI4P hydrolysis. Gβγ 
signaling is often associated with signaling 
via Gi proteins, but ET-1A receptors couple 
primarily to Gq. To determine whether Gi 
proteins were involved in the ET-1–medi-
ated response, we pretreated cells with per-
tussis toxin (PTX) before ET-1. PTX had no 
effect on ET-1–stimulated PI4P hydrolysis, 
indicating that Gi is not involved in this 
response.
Subcellular requirement for 
Gβγ-dependent PI4P hydrolysis
ET-1A receptors are present in the sarcolem-
mal membrane, whereas ET-1B receptors 
are present on intracellular membranes in 
ventricular myocytes (Bkaily et al., 2011). 
Acute stimulation of NRVMs with the ET-1 
peptide, however, should stimulate only re-
ceptors that are at least initially present on 
the cell surface. Previous data with the ET1A 
receptor–selective blocker BQ-123 indicate 
that ET-1–dependent PI4P depletion is de-
pendent on the ET-1A receptor (Zhang 
et al., 2013). Thus the question arises of 
whether Gβγ at the PM or at the Golgi is re-
quired for ET-1–dependent PI4P depletion. 
The Wedegaertner laboratory developed 
Golgi- and PM-targeted GRK2ct by fusing 
GRK2ct with the Golgi-targeting sequence 
KDELrD193N or the 66–amino acid PM-tar-
geting motif of Rit GTPase (Irannejad and 
Wedegaertner, 2010). These constructs 
have been extensively characterized to lo-
calize to the appropriate compartments in 
HeLa cells. When transfected into NRVMs, 
Golgi GRK2 was clearly targeted to the peri-
nuclear Golgi apparatus and colocalized ex-
clusively with a Golgi marker (Figure 3A). 
PM-targeted GRK2ct was more diffuse, but because of the flat na-
ture of these cells, a clear PM-associated fluorescent ring around the 
periphery of the cell is difficult to observe (Figure 3B); however, PM-
targeted GRK2ct had similar distribution as PM-targeted myris-
toylated and palmitoylated–yellow fluorescent protein (lyn-YFP), 
which is used extensively as a PM marker in other cell types (Teruel 
et al., 1999; Figure 3B). It is also clear that the Golgi-targeted 
GRK2ct shows no PM association and the PM-targeted GRK2ct 
shows no Golgi localization, speaking to the specificity of these in-
hibitors for these compartments. When NRVMs were transfected 
with PM-targeted GRK2ct, there was no effect on ET-1–stimulated 
Golgi PI4P hydrolysis (Figure 3, C and E). This is in stark contrast to 
the data in Figure 2C showing that cytosolic GRK2ct expression 
blocks ET-1–dependent PI4P depletion, indicating that restriction of 
GRK2ct to the PM prevents access to the pool of Gβγ that is relevant 
to stimulation of PI4P hydrolysis. On the other hand, transfection of 
NRVMs with Golgi-GRK2ct significantly inhibited ET-1–dependent 
ET-1. Stimulation with ET-1 leads to a time-dependent decrease in 
perinuclear PI4P–associated GFP-FAPP-PH fluorescence, as previ-
ously reported (Figure 2A). Pretreatment of NRVMs with 10 μM gal-
lein, a Gβγ blocker (Bonacci et al., 2006), completely inhibited ET-1–
dependent decrease in PI4P fluorescence. To control for potential 
nonspecific effects of gallein, we treated NRVMs with the Epac acti-
vator cpTOME to stimulate PLCε. cpTOME binding to Epac leads to 
activation of Rap, which in turn directly activates PLCε, resulting in 
perinuclear PI4P depletion (Bos, 2003; Zhang et al., 2013). Because 
this pathway is independent of Gβγ signaling, gallein would be pre-
dicted to have no effect on cpTOME-dependent depletion of peri-
nuclear PI4P. Treatment of NRVMs with cpTOME leads to PI4P deple-
tion, as previously reported, and pretreatment with 10 μM gallein 
does not alter this response (Figure 2B), indicating relative specificity 
of gallein for ET-1–dependent PI4P depletion.
To provide further evidence for Gβγ signaling controlling peri-
nuclear PI4P hydrolysis, we transfected NRVMs with the C-terminus 
FIGURE 2: Gβγ inhibitors block ET-1–stimulated perinuclear PI4P depletion in NRVMs. 
(A) NRVMs transfected with GFP-FAPP-PH were pretreated with 10 μM gallein or PBS vehicle 
control, followed by stimulation with 100 nM ET-1. Perinuclear FAPP fluorescence intensity was 
measured over time by confocal microscopy. (B) NRVMs were treated as in A, except that 10 μM 
cpTOME was added to stimulate PI4P hydrolysis. (C) NRVMs were cotransfected with GFP-
FAPP-PH and GRK2ct or vehicle control, followed by ET-1 stimulation as in A. (D) NRVMs were 
transfected as in A were pretreated for 18 h with 100 ng/ml pertussis toxin. All traces represent 
pooled data from at least three cells from three separate myocyte preparations ± SEM. The last 
five values from each time course were averaged and tested for significance using Student’s 
t test. ***p < 0.005; ns, not significant.
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that targeting Gβγ to the Golgi is sufficient to stimulate perinuclear 
PI4P hydrolysis and PKD activation.
Golgi-targeted GRK2ct blocks ET-1–stimulated 
cardiomyocyte hypertrophy
Overexpression of GRK2ct in cardiac myocytes has been well doc-
umented to block development of cardiomyocyte hypertrophy in 
vitro and in vivo (Koch et al., 1995; Rockman et al., 1998; Rengo 
et al., 2011). We showed that mAKAP-scaffolded PLCε hydrolyzes 
perinuclear PI4P at the perinuclear Golgi apparatus in cardiac myo-
cytes, and this is required for activation of nuclear PKD and cardio-
myocyte growth. The data presented thus far indicate that Gβγ can 
mediate activation of this hypertrophic pathway at the Golgi. This 
suggests the possibility that one of the mechanisms for the antihy-
pertrophic actions of GRK2ct is to block the Golgi perinuclear 
PLCε/PI4P/PKD pathway. To test this, we transfected NRVMs with 
plasmids expressing YFP alone or YFP plus GRK2ct, Golgi GRK2ct, 
or PM-GRK2ct. Twenty-four hours after infection, cells were treated 
with ET-1 for 24 h to induce hypertrophy (Figure 5). Because 
transfection efficiency of NRVMs was low, fluorescent cells were 
identified and hypertrophy was assessed by staining for increases 
in intracellular atrial natriuretic factor (ANF) levels with an anti-ANF 
antibody. ET-1 stimulated a robust increase in the level of ANF 
staining (Figure 5). In Figure 5A, the GRK2ct-transfected cell 
(green) shows no ET-1–induced ANF staining (red), whereas a 
neighboring untransfected cell shows robust ET-1–dependent ANF 
induction. Figure 5B shows representative images of cells trans-
fected with each of the constructs, and Figure 5C shows quantita-
tion of these data. Surprisingly, expression of either Golgi-GRK2ct 
or PM-GRK2ct prevented ET-1–dependent ANF induction. As an-
other measure of hypertrophy, the increase in cell size associated 
with ET-1–stimulated hypertrophy was assessed after adenoviral 
transduction of NRVMs with YFP, PM-GRK2ct, or Golgi-GRK2ct. 
Both Golgi- and PM-targeted GRK2ct blocked the ET-1–stimulated 
increase in cell size (Figure 6).
Neonatal cardiac myocytes are a standard model for examining 
signaling pathways associated with cardiac hypertrophy, but a 
more physiological model is the adult ventricular myocyte (AVM). 
AVMs were isolated from C57Bl6 mice and infected with adenovi-
ruses expressing a PIP2 detector, tubby-GFP, or a PI4P detector, 
FAPP-PH-GFP, as was done previously for NRVMs. Cells transfected 
with Tubby GFP showed localized PIP2-associated fluorescence at 
the sarcolemma (Figure 7A, top), whereas FAPP-PH-GFP detected 
PI4P at the perinuclear Golgi (Figure 7A, bottom). Some FAPP-PH-
GFP fluorescence was also observed in a pattern corresponding to 
Z-lines or T-tubules (Figure 7A, bottom). Thus, as in NRVMs, PIP2 is 
enriched at the PM in AVMs and is not observable at the perinu-
clear Golgi, indicating that the available PLC substrate at the Golgi 
is PI4P. We tested whether ET-1 treatment would lead to depletion 
of perinuclear PI4P as seen with NRVMs. ET-1 stimulated a time-
dependent decrease in perinuclear PI4P-associated fluorescence 
that was inhibited by treatment with gallein (Figure 7B).
To determine whether Golgi-GRK2ct can block ET-1–stimulated 
hypertrophy in AVMs, we infected cells with adenoviruses express-
ing either PM- or Golgi-targeted GRK2ct, followed by treatment 
with ET-1 for 24 h. Hypertrophy was assessed by ANF staining. As in 
the NRVMs, stimulation with ET-1 caused a robust increase in ANF 
expression that was inhibited by expression of either PM- or Golgi-
targeted GRK2ct (Figure 7, C and D).
Because either Golgi or PM GRK2ct can block hypertrophy, Gβγ-
mediated pathways at the PM or the Golgi are both required for 
cardiomyocyte hypertrophy. Golgi-targeted GRK2ct would not be 
PI4P hydrolysis, indicating that Gβγ signaling is required at the Golgi 
to stimulate perinuclear PI4P hydrolysis (Figure 3, D and E). Western 
blots of HEK293 cells or NRVMs transfected with PM or Golgi 
GRK2ct show similar levels of expression (Supplemental Figure S1).
We proposed that the role of perinuclear PI4P hydrolysis is to 
generate local DAG to maintain activation of a nuclear pool of PKD. 
PKD is then involved in phosphorylating HDAC and activation of 
hypertrophic gene expression. Because Golgi-GRK2ct blocked 
ET-1–dependent PI4P hydrolysis, we predicted that Golgi-GRK2ct 
would inhibit activation of the nuclear pool of PKD. NRVMs were 
cotransfected with a fluorescence resonance energy transfer (FRET)–
based reporter of PKD activity that is specifically targeted to the 
nucleus, nDKAR (Kunkel et al., 2007), with either Golgi- or PM-
targeted GRK2ct. ET-1 treatment of NRVMs led to a decrease in 
nDKAR FRET (indicative of phosphorylation by nuclear PKD), which 
was completely inhibited by cotransfection with Golgi-targeted 
GRK2ct (Figure 3, F–H). Targeting GRK2ct to the PM partially inhib-
ited nuclear PKD activation (Figure 3, F–H). These data indicate that 
Gβγ at the perinuclear Golgi in cardiac myocytes is required for nu-
clear PKD activation and that Gβγ activation at the PM is also par-
tially required for nuclear PKD activation.
Rapamycin-induced γ translocation to the Golgi induces 
PI4P hydrolysis and PKD activation
As an alternate approach to examining the role of Gβγ in different 
compartments, we used a rapamycin-inducible translocation 
system to specifically direct Gβγ to either the PM or the Golgi 
(Irannejad and Wedegaertner, 2010). In this system, FRB is fused to 
the C-terminus of the Gγ subunit and FKB is fused to either amino 
acids 1–11 of Lyn for PM targeting or KDELr-D193N for Golgi tar-
geting. To examine the effects of Gβγ targeting on perinuclear PI4P 
hydrolysis, we cotransfected NRVMs with Gβ1γ2-FRB, GFP-FAPP-
PH, and either PM or Golgi FKBP. Rapamycin-inducible transloca-
tion of Gβ1γ2-FRB to either PM (with Lyn-FKBP–cyan fluorescent 
protein [CFP]) or Golgi (KDELr-D193N-FKBP-CFP) has been demon-
strated in HeLa cells (Irannejad and Wedegaertner, 2010). Figure 4A, 
top, shows that GFP-Gβ becomes enriched in the perinuclear Golgi 
with rapamycin treatment. Figure 4A, bottom, shows localization of 
Golgi-targeted FKBP before and after 20 min of rapamycin treat-
ment. PM-dependent translocation was more difficult to observe, 
perhaps because of the diffuse PM localization observed in NRVMs 
(unpublished data; see Figure 2B). For measurement of PI4P deple-
tion, 24 h after cotransfection of FRB and FKBP constructs, rapamy-
cin was added, and perinuclear PI4P-associated GFP-FAPP-PH fluo-
rescence was monitored. Targeting Gβ1γ-FRB to the Golgi produced 
a strong stimulation of PI4P hydrolysis, whereas PM targeting of Gβγ 
had no effect (Figure 4B). In other cell types, forced translocation of 
Gβγ to the Golgi caused Golgi breakdown and vesiculation that 
could affect apparent PI4P-associated GFP-FAPP-PH fluorescence 
(Jamora et al., 1999; Irannejad and Wedegaertner, 2010). As shown 
in Figure 4A, rapamycin-induced translocation to the Golgi in 
NRVMs does not affect overall Golgi structure, since the Golgi-
targeted KDELr-D193N-FKBP-CFP localization and associated mor-
phology are not altered by rapamycin treatment under conditions in 
which PI4P fluorescence is dramatically decreased.
Targeting of Gβ1γ-FRB to the Golgi, but not the PM, also stimu-
lated nuclear PKD activation (Figure 4C). Rapamycin alone had no 
effect on PI4P hydrolysis or nuclear PKD activation (unpublished 
data). Although rapamycin dependent recruitment of Gβγ to the PM 
is not sufficient to activate nuclear PKD, it is possible that rapamy-
cin-dependent recruitment of Gβγ to the PM may not be capable of 
generating Gβγ signaling at the PM. Together these data indicate 
1192 | S. Malik et al. Molecular Biology of the Cell
FIGURE 3: Gβγ signaling at the Golgi apparatus stimulates perinuclear PI4P depletion in NRVMs and nuclear PKD 
activation. (A) NRVMs were transfected with Golgi-GRK2ct. GRK2ct localization was analyzed by immunocytochemistry 
with a GRK2 antibody with an Alexa Fluor 546–conjugated secondary antibody and imaged in the red channel. The 
Golgi-specific antibody (anti-Golgi 58K protein) was used to identify the Golgi apparatus, with Alexa Fluor 488 
secondary antibody imaged in the green channel. (B) Cells cotransfected with PM-GRK2ct, and myristoylated YFP to 
mark the PM, were analyzed for YFP fluorescence and GRK2ct localization as in A. (C) Cells were cotransfected with 
GFP-FAPP-PH and either LacZ or PM-GRK2ct constructs. Perinuclear GFP-FAPP-PH fluorescence was monitored with 
time after ET-1 addition. (D) Same as C, except that Golgi-targeted GRK2ct was used. (E) Quantitation of data in C and 
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required for hypertrophy development in 
cardiac myocytes.
DISCUSSION
Expression of GRK2ct in cardiomyocytes to 
block Gβγ signaling inhibits development 
of hypertrophy in vivo and in vitro (Koch 
et al., 1995; Rockman et al., 1998; Casey 
et al., 2010). Our laboratory has developed 
small molecule–based inhibitors of Gβγ 
that block interactions between Gβγ and 
various downstream protein targets, in-
cluding GRK2 (Bonacci et al., 2006). Gallein 
administration prevents development of 
heart failure in mice in several different 
models of hypertrophy (Casey et al., 2010). 
A model for the action of gallein and 
GRK2ct involves inhibition of GRK2 recruit-
ment by Gβγ downstream of the βAR. On 
the other hand, GRK2ct and gallein/M119 
are general Gβγ inhibitors that block multi-
ple signaling pathways. This raises the pos-
sibility that the efficacy of these reagents in 
prevention of heart failure may rest, at least 
in part, in their ability to inhibit other sig-
naling pathways downstream of Gβγ. In-
deed, pathways involving Gβγ-dependent 
regulation of ERK phosphorylation (Lorenz 
et al., 2009) and phosphoinositide 3-kinase 
γ (PI3Kγ) recruitment (Naga Prasad et al., 
2000; Nienaber et al., 2003; Prasad et al., 
2003) have potential involvement in regula-
tion of cardiac hypertrophy.
Here we identified another Gβγ path-
way that is required for cardiac hyper-
trophy, which we propose involves Gβγ-
dependent activation of PLCε at the 
perinuclear Golgi, downstream of the 
Gq- and G13-coupled ET-1A receptor. This 
proposal is based on the following obser-
vations: 1) Two different blockers of hyper-
trophy in vivo and in vitro—gallein and 
GRK2ct—block ET–1-dependent activa-
tion of Golgi PI4P hydrolysis in cardiac 
myocytes. 2) ET-1–dependent PI4P deple-
tion at the Golgi and subsequent PKD acti-
vation requires PLCε (Zhang et al., 2013) and is blocked by a 
Golgi-targeted Gβγ blocker (Golgi-GRK2ct). 3) Gβγ is a known up-
stream regulator of PLCε (Wing et al., 2001). 4) PLCε is required for 
development of cardiac hypertrophy in vivo and in vitro (Zhang 
et al., 2011, 2013). Although it is formally possible that blockade 
of Gβγ signaling at the Golgi inhibits hypertrophy development 
through a parallel pathway that does not involve regulation of 
expected to influence PM GPCR desensitization mechanisms such as 
GRK2 recruitment and instead involve inhibition of the hypertrophic 
Golgi PLCε/PI4P signaling pathway. PM-targeted GRK2ct has the po-
tential block the Golgi PLCε/PI4P pathway by preventing Gβγ trans-
location from the PM to the Golgi, but the data in Figure 2C indicate 
that PM-GRK2ct has no effect on Golgi PI4P hydrolysis. This indicates 
that two independent PM and Golgi Gβγ-mediated pathways are 
FIGURE 4: Targeting Gβγ to the Golgi apparatus stimulates PI4P hydrolysis and nuclear PKD 
activation. (A) Cells were transfected with mCherry-Gβ1, Gγ2FRB, and CFP-Golgi-FKBP. mCherry 
fluorescence (top two) and CFP fluorescence (bottom two) before and 10 min after rapamycin 
addition. (B) NRVMs were transfected with GFP-FAPP-PH, Gβ1, Gγ2FRB, and either CFP-Golgi-
FKBP or PM-FKBP. At time 0, 24 h after transfection, 10 μM rapamycin was added, and 
perinuclear PI4P fluorescence was monitored with time. (C) Cells were transfected with Gβ1, 
Gγ2FRB, and nDKAR and either PM-FKBP or Golgi FKBP. At time 0, 24 h after transfection, 
10 μM rapamycin was added, and nDKAR YFP/CFP fluorescence in the nucleus was monitored. 
All traces represent pooled data from at least three cells from three separate myocyte 
preparations ± SEM. Scale bars, 10 μm.
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Scale bars, 10 μm.
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where modification of both Gα and Gγ with lipids is sufficient to 
maintain PM localization of a Gαβγ heterotrimer. The model sug-
gests that when these subunits dissociate, the single lipid modifica-
tion on the γ subunit is not sufficient to retain the Gβγ complex at the 
PM, and a new equilibrium is established in which Gβγ can equili-
brate to internal membranes such as the Golgi (O’Neill et al., 2012). 
Alternatively, transport of Gβγ in endosomes with or without internal-
ization of cell surface ET-1A receptors could result in accumulation of 
free Gβγ in the Golgi. Finally, it is possible that activation of ET1A 
signaling at the PM could generate a signal at the PM that could dif-
fuse to the Golgi to activate heterotrimers resident at the Golgi. A 
possible candidate for this might be an activator of G protein signal-
ing (AGS) protein that can stimulate Gβγ release from Gα subunits in 
a receptor-independent manner (Blumer et al., 2007). It was recently 
that AGS3 can translocate from the PM to the Golgi in response to 
receptor activation (Oner et al., 2013). Defining which, if any, of these 
mechanisms mediates this signal requires further investigation.
These observations have clinical significance with respect to 
design of inhibitors to inhibit development of heart failure. Recent 
PLC, the simplest model that can account for the data involves 
activation of PLCε by Gβγ at the Golgi.
We also show that expression of either PM- or Golgi-targeted 
GRK2ct inhibits development of cardiac hypertrophy but that PM 
targeting of GRK2ct does not affect perinuclear PI4P hydrolysis. This 
indicates that there are independent roles for Gβγ at the PM and the 
Golgi and that requirement for Gβγ at the PM is not to regulate the 
Golgi PI4P hydrolysis pathway. We showed that the PLC/PI4P hydro-
lysis pathway at the Golgi is required for ET-1–dependent hypertro-
phy but not that it is sufficient to drive hypertrophy. We propose that 
a second parallel signal is dependent on Gβγ activity at the PM and 
is also required for stimulation of hypertrophy. This could involve 
GRK2, PLC, or an undefined effector at the PM.
A major open question is how ET-1, through activation of ET-1AR 
at the PM, leads to Gβγ signaling at the perinuclear Golgi apparatus. 
One possibility is diffusion-based translocation of Gβγ from the 
PM to the Golgi. Translocation of fluorescently labeled G protein βγ 
subunits from the PM to the Golgi was demonstrated (Saini et al., 
2007). This was proposed to rely on dissociation of Gα from Gβγ, 
FIGURE 5: Blocking Gβγ signaling in the Golgi or PM prevents ET-1–stimulated hypertrophic gene expression in 
NRVMs. (A) NRVMs were cotransfected with YFP and GRK2ct, followed by treatment with 100 nM ET-1 or vehicle. After 
24 h, cells were fixed and stained for ANF (red). With ET-1 treatment, the intensity of red staining increases in 
untransfected cells but not in cells expressing YFP and GRK2ct. Scale bar, 40 μm. (B) Cells were transfected with YFP 
alone or YFP plus GRK2ct, Golgi GRK2ct, or PM-GRK2ct. Cells were treated as in A. Scale bar, 20 μm. (C) The intensity 
of ANF staining was quantitated with and without ET-1 only in transfected cells identified by YFP fluorescence. 
Quantitation is based on combined data (mean ±SEM) from four separate experiments. ****p < 0.0001, statistically 
different from YFP control. None of the other samples is statistically different from YFP control (one-way ANOVA).
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therapeutic approaches to heart failure are considered, a global Gβγ 
inhibition strategy might have high efficacy due to multiple target 
inhibition, but there may be advantages to targeting Gβγ signaling 
at specific cellular locations such as the Golgi apparatus that could 
avoid potential side effects of global Gβγ inhibition or even Gβγ 
signaling at the PM. This remains to be explored in more-physiolog-
ical animal models of heart failure.
MATERIALS AND METHODS
Materials
ET-1 was purchased from Sigma-Aldrich (St. Louis, MO). Gallein 
was from TCI America (Portland, OR), dissolved in phosphate-buff-
ered saline (PBS), and titrated to pH 7.8 with NaOH to create a 
15 mg/ml stock that was stored in aliquots at −20°C. Rapamycin 
and cpTOME were from EMD Millipore (Billerica, MA).
Adenoviral constructs and plasmids
The EGFP-FAPP-PH domain (N-terminal EGFP fusion) for detection 
of PI4P was as previously described (Balla et al., 2005, 2009). GFP-
Tubby (Santagata et al., 2001; Balla et al., 2009) and GFP-PLCδ-PH 
(Balla and Varnai, 2002) for detection of PIP2 were also previously 
described. nDKAR (Kunkel et al., 2007) was provided by Alexandra 
Newton (University of California, San Diego, CA). nDKAR was 
inserted into an adenovirus vector by standard methods. Gγ2-
C68S-FRB, PM-FKBP (LF2C, Lyn1-11-FKBP(X2)-CFP), and Golgi-
FKBP (KDELr-D193N-FKBP(x2)-CFP), Golgi-GRK2ct (KEDLrD193N-
GRK2(495-689)), and PM-GRK2ct (GRK2(495-689)-Rit) were 
constructed as previously described (Irannejad and Wedegaertner, 
2010). Adenoviruses were constructed using a vector expressing 
YFP from one promoter and PM-GRK2ct, Golgi-GRK2ct, or GFP-
Tubby from a second cytomegalovirus promoter.
Antisera
Anti-GRK2 was from Santa Cruz Biotechnology (Dallas, TX; 1:100); 
rabbit polyclonal affinity-purified anti-ANF was from EMD Millipore. 
Golgi protein, 58K protein (1:250), monoclonal antibody (58K-9) was 
from Thermo Fisher Scientific (Waltham, MA). mAKAP antibody was 
kindly provided by Michael Kapiloff (University of Miami School of 
Medicine, Miami, FL).
nDKAR FRET
NRVMs were transduced with an nDKAR-expressing adenovirus. 
After 48 h, FRET was analyzed by confocal microscopy on an Olym-
pus FV1000MP microscope. Transduced cells were identified by 
exciting CFP at 440 nm and emission monitored at 480 nm. FRET 
was determined by measuring the ratio of YFP emission at 535 nm 
to CFP emission at 480 nm after CFP excitation at 440 nm. Be-
cause the YFP and CFP are fused in this construct, it is not neces-
sary to correct for expression or spectral bleedthrough of the vari-
ous constructs. Data were normalized to the initial YFP/CFP ratio in 
each set at an arbitrary value of 1.
Isolation of cardiac myocytes
NRVMs were isolated from 2- to 3-d-old Sprague Dawley rats and 
cultured essentially as described (Zhang et al., 2011). Adult myo-
cytes were isolated from 4- to 6-mo-old wild-type mice as previously 
described (Oestreich et al., 2009).
Transfection and transduction of NRVMs and AVMs
NRVMs cultured for 2 d were transfected with 1–2 μg of the indi-
cated plasmid constructs or transduced with 50 multiplicity of 
infection (MOI) of the indicated viruses. Adenoviral transduction 
FIGURE 6: Blocking Gβγ signaling in the Golgi or PM prevents 
ET-1–stimulated cardiomyocyte hypertrophic cell growth. (A) NRVMs 
were infected with adenoviruses expressing YFP or YFP and the 
indicated targeted GRK2ct constructs. Cells were treated with 100 nM 
ET-1 or vehicle. After 48 h, cells were visualized in the YFP channel. 
Scale bar, 40 μm. (B) Cells treated as in A quantitated for cell area 
using ImageJ (National Institutes of Health, Bethesda, MD). 
Quantitation is based on combined data (mean ±SEM) from three 
separate experiments; 50 cells each experiment. Data were analyzed 
by one-way ANOVA; ***p < 0.005.
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efforts have focused on development of inhibitors of GRK2 that im-
prove cardiac performance and may prevent development of heart 
failure (Thal et al., 2011, 2012). The data presented here suggest 
that although directly targeting GRK2 may be effective, a strategy 
that targets Gβγ may have greater efficacy due to its ability to block 
multiple hypertrophic signaling pathways. The list of Gβγ-dependent 
pathways that regulate cardiac hypertrophy continues to grow and 
include PI3Kγ (Prasad et al., 2003; Perrino et al., 2006) and ERK acti-
vation (Lorenz et al., 2009; Ruppert et al., 2013), to which we now 
add Gβγ-regulated PLC activity at the Golgi. We also observed that 
Gβγ inhibition at the PM inhibits hypertrophy in NRVMs but have not 
characterized the underlying signaling mechanism. As new 
1196 | S. Malik et al. Molecular Biology of the Cell
FIGURE 7: Blocking Gβγ signaling in the Golgi or PM prevents ET-1–stimulated ANF expression in AVMs. (A) AVMs were 
infected with adenoviruses expressing either Tubby-GFP (top) or GFP-FAPP-PH (bottom). (B) AVMs were infected with 
GFP-FAPP-PH and stimulated with 100 nM ET-1, and perinuclear GFP-FAPP-PH was monitored over time as indicated. 
Each trace represents pooled data from at least five cells from five separate myocyte preparations ± SEM. (C) AVMs were 
infected with viruses (50 MOI) expressing YFP, Golgi-GRK2ct, or PM-GRK2ct (only cells expressing YFP or Golgi-GRK2ct 
are shown). Viruses expressing Golgi-GRK2ct and PM-GRK2ct also expressed YFP from a separate cassette. Cells were 
stimulated for 24 h with 100 nM ET-1 and fixed and stained for ANF expression. (D) ANF expression was quantitated as 
mean ± SEM for all treatments as described in Materials and Methods. ****p < 0.0001, statistically different from YFP 
control. None of the other samples is statistically different from YFP control (one-way ANOVA). Scale bars, 10 μm.
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averaged based on individual cells (>40 cells total) pooled from 
three separate experiments for NRVMs and AVMs.
efficiency was >90%, and plasmid-based transfection efficiency was 
∼5%. Cells were examined 24 h later by microscopy or as indicated 
for measurement of nDKAR FRET or GFP-FAPP-PH fluorescence.
Confocal microscopy
Myocytes transfected with plasmids or transduced adenoviruses ex-
pressing enhanced GFP (EGFP)–, YFP-, or mCherry-tagged proteins 
were analyzed in an Olympus FV1000MP microscope in confocal 
mode with a LUMPLFL 40×/0.8 numerical aperture W (Olympus, 
Tokyo, Japan) lens. EGFP was excited at 488 nm and emission moni-
tored at 510 nm, YFP was excited at 515 nm and emission moni-
tored at 527 nm, mCherry and monomeric red fluorescent protein 
were excited at 559 nm and emission monitored at 618 nm, CFP 
was excited at 440 and emission monitored at 476 nm, and 4′,6-di-
amidino-2-phenylindole was excited at 405 nm and emission moni-
tored at 461 nm. During imaging, cells were in culture medium con-
taining serum.
Western blotting
Membranes were blocked in 5% milk in Tris-buffered 
saline/0.1%Tween 20 (TBST) for 2 h at room temperature. After 
three washes (5 min each) with TBST, the membranes were incu-
bated with anti-GRK2 antibody (1:3000) in 3% bovine serum albu-
min (BSA) in TBST overnight at 4°C. After incubation, membranes 
were washed four times with TBST (10 min each) and incubated with 
anti-rabbit secondary antibody (1:10,000, IR-800; LI-COR Biosci-
ences, Lincoln, NE) in 5% milk in TBST for 1 h at room temperature. 
Blocking was for 1 h at room temperature, and primary antibody 
was incubated for 2 h at room temperature and secondary antibody 
for 1 h at room temperature. The membranes were washed three 
times with TBST (10 min each) and scanned on a LI-COR Odyssey 
infrared imaging system.
Immunocytochemistry for ANF induction
NRVMs were transfected with 1 μg of empty vector, GRK2ct, PM-
GRK2ct, or Golgi-GRK2ct and 1 μg of a YFP-expressing plasmid us-
ing Lipofectamine 2000 to allow identification of transfected cells. 
Sixteen hours after transfection 100 nM ET-1 was added for 24 h to 
induce hypertrophy. Cells were briefly washed with PBS and fixed 
for 25 min in a solution of 2% paraformaldehyde (Sigma-Aldrich) 
with 0.025% glutaraldehyde (J.T. Baker, Center Valley, PA) in PBS. 
After permeabilization in 0.2% Triton X-100 for 15 min at room tem-
perature, cells were blocked in a solution of 10% BSA in PBS for 1 h 
at room temperature. Primary antibody (rabbit anti-ANF [EMD 
Millipore]) was incubated at a dilution of 1:2500 in PBS overnight at 
4°C. After three washes in PBS, cells were incubated with the sec-
ondary antibody (goat anti-rabbit Alexa Fluor 546 [Life Technolo-
gies, Grand Island, NY]) at a 1:2500 dilution in PBS for 3 h at room 
temperature. Fluorescence images were captured by confocal mi-
croscopy and analyzed for ANF expression.
For AVMs, freshly isolated adult myocytes from mice were in-
fected with adenoviruses expressing YFP, PM-GRK2ct, or Golgi-
GRK2ct for 2 h, after which the virus was removed by washing and 
the contraction inhibitor blebbistatin was added to the culture me-
dium. At 16 h later, cells were treated with either vehicle or 100 nM 
ET-1 for 24 h. Cells were fixed and stained for ANF as described.
To quantitate ANF induction, fluorescence images were cap-
tured by confocal microscopy, and transfected YFP fluorescent cells 
were identified and analyzed for ANF fluorescence intensity using 
Olympus FluoView software, version 2.0a. Perinuclear area was 
traced, and peak ANF intensity was measured for each cell minus 
background subtraction from area in the cytosol. Data were 
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